1 Min Read
BRUSSELS (Reuters) - Belgian investment fund Gimv (GIMV.BR) said it sold its remaining stake in biotech firm Ablynx (ABLX.BR) after partnering the company for 12 years.
Gimv said the exit has a positive impact of 3.8 million euros on its last published equity value, and it would use the proceeds to make other investments in the biotech sector.
Reporting by Robert-Jan Bartunek
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.